| Old Articles: <Older 3131-3140 Newer> |
|---|
 |
The Motley Fool
September 21, 2006
Brian Lawler |
Sayonara, Serono The tiny, struggling drugmaker succumbs to a surprise buyout by German pharmaceutical company Merck KGaA. Investors, take note.   |
The Motley Fool
September 21, 2006
Brian Lawler |
Another Partner for Biogen The pharmaceutical enlists help to thwart a troublesome illness. After the market closed yesterday, Biogen added another collaboration agreement with Alnylam Pharmaceuticals to its long list of partners. Investors, take note. |
The Motley Fool
September 19, 2006
Brian Lawler |
Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr. |
The Motley Fool
September 19, 2006
Brian Lawler |
A Long Wait for MannKind The company's inhaled insulin might not reach the market for several years, if it does, but it's a big market. Investors, take note. |
Bio-IT World
September 2006
Kevin Davies |
The $2 Billion Pill? Challenges and opportunities facing the drug industry were recurring themes in the quartet of keynote speeches at the 2006 Drug Discovery Technology conference. |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
Bio-IT World
September 2006
John A. Wass |
Integrating Knowledge The results of new mathematical routines have the potential to save pharmaceuticals millions of dollars in drug development. And yet the flow of successful drugs is dwindling. The problem goes beyond bureaucracy and lies in the complexity of the problem. |
Bio-IT World
September 2006
Wayne R. Kubick |
Data Standards: Are We at the Tipping Point? A decade ago, the prospect of defining standards for representing clinical data was deemed impossible by many in the drug discovery industry, yet a large number of standards-related activities are rapidly converging. So, are we nearing a tipping point? Let's look at the evidence. |
The Motley Fool
September 18, 2006
Brian Lawler |
Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note. |
BusinessWeek
September 25, 2006
Michael Mandel |
What's Really Propping Up The Economy Since 2001, the health-care industry has added 1.7 million jobs. The rest of the private sector? None. |
| <Older 3131-3140 Newer> Return to current articles. |
